StocksMedium•12 November 2026•
1 min read
Vir Biotechnology Announces Proposed Public Offering of Common Stock
Key Facts
1Vir Biotechnology announced its intention to offer shares of its common stock in an underwritten public offering.
2The company intends to grant underwriters a 30-day option to purchase up to an additional 15% of the number of shares offered.
Vir Biotechnology announced its intention to offer shares of its common stock in an underwritten public offering, according to Business Wire. The company intends to grant underwriters a 30-day option to purchase up to an additional 15% of the number of shares offered.
The company is seeking to raise funds for its clinical-stage biopharmaceutical operations focused on infectious diseases and cancer. VIR closed at $13.13 on November 11, 2026, prior to the announcement of the offering which typically results in share price dilution.